## AMENDMENTS TO THE CLAIMS

Claims 1-72 (Cancelled).

73. (Currently amended) ~~The solid composition of claim 72~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

74. (Cancelled)

75. (Currently amended) ~~The solid composition of claim 72~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

76-79. (Cancelled)

80. (Currently amended) ~~The solid composition of claim 79~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

81. (Currently amended) ~~The solid composition of claim 79~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

82-89. (Cancelled)

90. (Currently amended) ~~The solid composition of claim 89~~ A solid composition comprising about 5 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

91-92. (Cancelled)

93. (Previously presented) A solid composition whose ingredients comprise:

| INGREDIENT | mg/composition |
|---|---|
| Desloratadine, micronized | 5.0 |
| Corn Starch NF/Ph. Eur. | 36.0 |
| Microcrystalline Cellulose NF/Ph. Eur./JP | 132.7 |
| Edetate Disodium USP | 10.0 |
| Citric Acid Anhydrous, USP | 10.0 |
| Stearic Acid, NF. | 6.0 |
| Dye | 0.3 |
| TOTAL | 200.0 |

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

94. (Previously presented) The solid composition of claim 93 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

95. (Previously presented) A solid composition whose ingredients comprise:

| INGREDIENT | mg/composition |
|---|---|
| Desloratadine, micronized | 2.5 |
| Corn Starch NF/Ph. Eur. | 18.0 |
| Microcrystalline Cellulose NF/Ph. Eur./JP | 66.35 |
| Edetate Disodium | 5.0 |
| Citric Acid | 5.0 |

| | |
|---|---|
| Stearic Acid USP/Ph. Eur. | 3.0 |
| Dye | 0.15 |
| TOTAL | 100.00 |

and wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

96. (Previously presented) The solid composition of claim 95 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

97. (Cancelled)

98. (Cancelled)

99. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 72.~~ claim 75.

100. (Cancelled)

101. (Currently amended) ~~The solid composition of claim 100~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of two pharmaceutically acceptable antioxidants, wherein total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

102-104. (Cancelled)

105. (Currently amended) ~~The solid composition of claim 103~~ A solid composition comprising about 2.5 mg desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

106. (Previously presented) A solid composition whose ingredients comprise:

| INGREDIENT | mg/composition |
|---|---|
| Desloratadine, micronized | 5.0 |
| Corn Starch NF/Ph. Eur. | 36.0 |
| Microcrystalline Cellulose NF/Ph. Eur./JP | 140.7 |
| Edetate Disodium | 10.0 |
| Citric Acid | 2.0 |
| Talc NF/Ph. Eur. | 6.0 |
| Dye | 0.3 |
| TOTAL | 200.0 |

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

107. (Previously presented) The solid composition of claim 106 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

108. (Previously presented) A solid composition whose ingredients comprise:

| INGREDIENT | mg/composition |
|---|---|
| Desloratadine, micronized | 2.5 |
| Corn Starch NF/Ph. Eur. | 18.0 |
| Microcrystalline Cellulose NF/Ph. Eur./JP | 70.35 |
| Edetate Disodium | 5.0 |
| Citric Acid | 1.0 |
| Talc NF/Ph. Eur. | 3.0 |
| Dye | 0.28 |
| TOTAL | 100.00 |

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

109. (Previously presented) The solid composition of claim 108 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

110-116. (Cancelled)

117. (Curently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 102.~~ claim 101.

118. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 103.~~ claim 105.

119. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

120. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.

121. (New) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 73.